echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Haussen Pharmaceuticals' Shagritin tablets will be approved as the third domestically produced.

    Haussen Pharmaceuticals' Shagritin tablets will be approved as the third domestically produced.

    • Last Update: 2020-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 12, Jiangsu Haussen Pharmaceuticals 4 classes of generic drug shagritin tablets market application (acceptance number: CYHS1800448/9) NMPA processing status changed to "in approval", is expected to be approved in recent days and as if through a consistent evaluation, become the third domestic.
    from: NMPA official website Saxaglipti is an efficient dipeptide-based peptide enzyme-4 (DPP-4) inhibitor that regulates blood sugar by selectively suppressing DPP-4, raising endogenetic glucoglycline-like peptide-1 (GLP-1) and glucose-dependent insulin-based insulin-releasing polypeptide (GIP) levels and regulating blood sugar, primarily for the treatment of type 2 diabetes in adults.
    compared with traditional sugar-lowering drugs, THE DPP-4 inhibitors have the advantage of not increasing the risk of hypoglycemia, neutral weight effects, and good cardiovascular safety.
    Shagritin was first developed by Shishi Shiguibao Pharmaceuticals and was approved by the FDA in 2009 for listing under the product name: Onglyza®/Anizer ®, which was acquired by AstraZeneca, and was approved to enter the Chinese market in May 2011 and has been included in The Health Insurance Category B list since 2017.
    Currently, five varieties (unilateral) of DPP-4 inhibitors, including shagritin, are listed in China, and the remaining four varieties are Sigletin, Viglitin, Aglitin and Liglitin, all of which are listed in The Health Insurance Category B and are listed as domestic generics.
    It is worth noting that Viglitin is one of the largest number of generic drug listed enterprises, in addition to the original research has been approved for the listing of 8 generic drugs in China, in the third batch of national collection with a maximum of 89% (non-difference ratio) of the decline in the winning bid.
    's approved DPP-4 inhibitor data as of September 28, 2020 From sample hospital data for 2012-2017, Shagritin's sales in China increased year by year, with sample hospital sales exceeding 40 million in 2017 and global sales reaching 4.5 billion.
    data source: Zhejiang Securities Insight database shows that shagritin tablets are currently in addition to the original research AstraZeneta, Jiangsu Osaikang (first imitation) and Zhengda Tianqing (two imitations) have been approved for listing, the enterprises that submitted the listing application in addition to Howson, Qilu Pharmaceuticals;
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.